Royalty pharma plc RPRX 深 沪
等待开盘 08-20 09:30:00 美东时间
61.73
+2.040
+3.42%
华盛通- 最 高61.80
- 今 开60.12
- 成交量 325.33万股
- 最 低 59.75
- 昨 收 59.69
- 总市值 354.95亿
- 52周最高 61.80
- 市盈率 静 34.65
- 换手率 0.57%
- 52周最低 33.1555
- 委 比 -98.91%
- 总股本 5.75亿
- 历史最高 61.80
- 量 比 1.30
- 振 幅 3.43%
- 历史最低 22.465
- 每 手 1
- 风险率 8.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market capitalization of $26.09 billion. Buying $100 In RPRX: If an investor had bought $100 of RPRX stock 10...
08-15 06:46
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Zealand gains $100M in funding from Royalty Pharma
Royalty Pharma (RPRX) will provide $100M in funding to Zealand Pharma (ZLDPF) in exchange for a royalty for rusfertide (PTG-300), its candidate from the rare blood disease polycythemia vera. Terms cal...
08-13 05:16
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
08-08 00:46
财报速睇 | Royalty pharma plc 2026财年Q2营收6.74亿美元，同比增长16.5%；归母净利润0.18亿美元，同比下滑44.4%
华盛资讯8月5日讯，Royalty pharma plc公布2026财年Q2业绩，公司Q2营收6.74亿美元，同比增长16.5%，归母净利润0.18亿美元，同比下滑44.4%。
08-05 21:20
财报速睇 | Royalty pharma plc 2026财年Q2营收6.74亿美元，同比增长16.4%；归母净利润0.18亿美元，同比下滑43.8%
华盛资讯8月5日讯，Royalty pharma plc公布2026财年Q2业绩，公司Q2营收6.74亿美元，同比增长16.4%，归母净利润0.18亿美元，同比下滑43.8%。
08-05 19:52
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $674.000 million w...
08-05 19:27
Royalty Pharma reports Q2 results
Royalty Pharma press release (RPRX): Q2 net income of $81M Revenue of $674M (+16.4% Y/Y) misses by $84.88M. Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Raised full ...
08-05 19:13
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Monday. Shares of AstraZeneca PLC (NYSE:AZN) dipped 6% to $159.54 in pre-market trading. AstraZeneca is reportedly in discussions with Bristol Myers Squibb (NYSE:BMY) to merge, potentially forming a pharma...
08-03 20:01
